000 06195nam a22005775i 4500
001 978-3-031-69491-2
003 DE-He213
005 20251030113320.0
007 cr nn 008mamaa
008 241120s2024 sz | s |||| 0|eng d
020 _a9783031694912
_9978-3-031-69491-2
024 7 _a10.1007/978-3-031-69491-2
_2doi
050 4 _aRC434.2-574
072 7 _aMMH
_2bicssc
072 7 _aMED105000
_2bisacsh
072 7 _aMKL
_2thema
245 1 0 _aNeurophysiologic Biomarkers in Neuropsychiatric Disorders
_h[electronic resource] :
_bEtiologic and Treatment Considerations /
_cedited by Daniel C. Javitt, James C. McPartland.
250 _a1st ed. 2024.
264 1 _aCham :
_bSpringer Nature Switzerland :
_bImprint: Springer,
_c2024.
300 _aXXIII, 831 p. 146 illus., 127 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAdvances in Neurobiology,
_x2190-5223 ;
_v40
505 0 _aIntroduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry – An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson’s Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry.
520 _aThis book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson’s disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development.
650 0 _aPsychiatry.
_970761
650 0 _aNeurosciences.
_968384
650 0 _aNeurology .
_966816
650 0 _aPharmacology.
_967844
650 1 4 _aPsychiatry.
_970761
650 2 4 _aNeuroscience.
_968386
650 2 4 _aNeurology.
_966816
650 2 4 _aPharmacology.
_967844
700 1 _aJavitt, Daniel C.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_987778
700 1 _aMcPartland, James C.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_973294
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031694905
776 0 8 _iPrinted edition:
_z9783031694929
776 0 8 _iPrinted edition:
_z9783031694936
830 0 _aAdvances in Neurobiology,
_x2190-5223 ;
_v40
_972663
856 4 0 _uhttps://doi.org/10.1007/978-3-031-69491-2
912 _aZDB-2-SBL
912 _aZDB-2-SXB
999 _c65078
_d65078